Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Chinese Patients With Chronic Spontaneous Urticaria
NCT03328897Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2017
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab in chronic spontaneous urticaria (CSU), sponsored by Novartis. Started Apr 2017; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT03328897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03328897.